Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-05-10 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
ECDC report shows rising HAIs and antibiotic use
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the London Stock Exchange's 'Reach' service. It discusses a third-party report from the ECDC regarding antibiotic resistance and highlights how the company's technology addresses this issue. It is explicitly labeled as a 'Non-regulatory announcement' and does not constitute a formal financial report, proxy, or governance filing. As it is a general corporate announcement that does not fit into specific categories like earnings or M&A, it falls under the RNS (Regulatory Filings) category.
2024-05-10 English
Further Result of Fundraising
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Ondine Biomedical Inc. regarding the 'Further Result of Fundraising', specifically detailing an increase in the amount raised through a placing and subscription of new common shares. It includes details on the number of shares issued, the issue price, the impact on total voting rights, and the expected admission to trading on AIM. This falls under the category of capital raising and share issuance announcements.
2024-05-08 English
Result of Fundraising
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding the successful completion of a fundraising event (placing and subscription of new common shares). It details the gross proceeds, the number of shares issued, the involvement of directors in the subscription (related party transaction), and the expected admission to trading on AIM. This falls squarely under the definition of a capital/financing update, as it describes the company's fundraising activities and changes to its capital structure.
2024-05-03 English
Ondine announces proposed fundraising
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding a proposed fundraising through a placing and subscription of new common shares. It details the purpose of the funds, the pricing, the involvement of directors, and the expected timetable for the transaction. This falls squarely under the definition of a capital/financing update as it describes the company's fundraising activities and capital structure changes.
2024-05-03 English
Related Party Transactions
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from Ondine Biomedical Inc. regarding 'Related Party Transactions' involving a director and a substantial shareholder. It details specific financial arrangements (a director payment and a loan) made in anticipation of a future fundraising event. While it mentions fundraising, it is not a formal capital raise document itself, but rather a disclosure of related party transactions under AIM rules. Therefore, it fits best under the 'Regulatory Filings' (RNS) category as it is a standard regulatory disclosure announcement.
2024-05-02 English
New study confirms nose is key source of infection
Regulatory Filings Classification · 98% confidence The document is a press release issued via the RNS Reach service. It discusses independent research findings regarding surgical site infections and how the company's product, Steriwave, addresses these issues. It is a non-regulatory announcement intended for public relations and information dissemination rather than a mandatory financial filing. Since it does not fit into specific categories like financial reports, governance, or shareholder voting, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous corporate announcements.
2024-04-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.